Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis
Background. Acute myocardial infarction (AMI) is a disease with high morbidity and mortality. Some new biomarkers can help us to improve the life quality and prognosis of AMI patients. Objective. We therefore performed a systematic review and meta-analysis on the use of galectin-3 (gal3) for assessi...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Cardiology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2020/7614327 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554374493110272 |
|---|---|
| author | Lei Tian Kan Chen Zhihua Han |
| author_facet | Lei Tian Kan Chen Zhihua Han |
| author_sort | Lei Tian |
| collection | DOAJ |
| description | Background. Acute myocardial infarction (AMI) is a disease with high morbidity and mortality. Some new biomarkers can help us to improve the life quality and prognosis of AMI patients. Objective. We therefore performed a systematic review and meta-analysis on the use of galectin-3 (gal3) for assessing prognosis of AMI patients. Methods. We searched Medline, Embase, Web of Science, Cochrane Library, SinoMed, China National Knowledge Infrastructure (CNKI), and Wanfang database up to June 2019. Trials included using galectin-3 to estimate prognosis in myocardial infarction (MI) patients. Results. We identified 10 trails with a total of 2809 participants. The negative correlation between galectin-3 and left ventricular ejection fraction (LVEF) was significant in 505 AMI patients (Fisher's Z −0.22, 95% CI: −0.34, −0.09). The correlation between galectin-3 and infarct size was not significant in 119 patients (Fisher's Z 0.12, 95% CI: −0.36, 0.60). Higher galectin-3 was associated with increased all-cause mortality in 2343 AMI patients (Fisher's Z 1.58, 95% CI: 1.23, 2.03). Conclusion. The limited evidence suggests that galectin-3 is likely to predict the adverse outcomes in MI patients, but it is not significantly correlated with infarct size after MI. More high-quality trials with longer-term follow-up are still needed to confirm this finding. |
| format | Article |
| id | doaj-art-9bb56c88ce3f43088da127ee80d7f651 |
| institution | Kabale University |
| issn | 2090-8016 2090-0597 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cardiology Research and Practice |
| spelling | doaj-art-9bb56c88ce3f43088da127ee80d7f6512025-02-03T05:51:46ZengWileyCardiology Research and Practice2090-80162090-05972020-01-01202010.1155/2020/76143277614327Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-AnalysisLei Tian0Kan Chen1Zhihua Han2Department of Cardiology, Shanghai General Hospital, Shanghai Jiaotong University, 100 Haining Road, Shanghai, ChinaDepartment of Cardiology, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiaotong University, 639 Zhizaoju Road, Shanghai, ChinaDepartment of Cardiology, Shanghai Ninth People’s Hospital, School of Medicine, Shanghai Jiaotong University, 639 Zhizaoju Road, Shanghai, ChinaBackground. Acute myocardial infarction (AMI) is a disease with high morbidity and mortality. Some new biomarkers can help us to improve the life quality and prognosis of AMI patients. Objective. We therefore performed a systematic review and meta-analysis on the use of galectin-3 (gal3) for assessing prognosis of AMI patients. Methods. We searched Medline, Embase, Web of Science, Cochrane Library, SinoMed, China National Knowledge Infrastructure (CNKI), and Wanfang database up to June 2019. Trials included using galectin-3 to estimate prognosis in myocardial infarction (MI) patients. Results. We identified 10 trails with a total of 2809 participants. The negative correlation between galectin-3 and left ventricular ejection fraction (LVEF) was significant in 505 AMI patients (Fisher's Z −0.22, 95% CI: −0.34, −0.09). The correlation between galectin-3 and infarct size was not significant in 119 patients (Fisher's Z 0.12, 95% CI: −0.36, 0.60). Higher galectin-3 was associated with increased all-cause mortality in 2343 AMI patients (Fisher's Z 1.58, 95% CI: 1.23, 2.03). Conclusion. The limited evidence suggests that galectin-3 is likely to predict the adverse outcomes in MI patients, but it is not significantly correlated with infarct size after MI. More high-quality trials with longer-term follow-up are still needed to confirm this finding.http://dx.doi.org/10.1155/2020/7614327 |
| spellingShingle | Lei Tian Kan Chen Zhihua Han Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis Cardiology Research and Practice |
| title | Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis |
| title_full | Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis |
| title_fullStr | Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis |
| title_full_unstemmed | Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis |
| title_short | Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis |
| title_sort | correlation between galectin 3 and adverse outcomes in myocardial infarction patients a meta analysis |
| url | http://dx.doi.org/10.1155/2020/7614327 |
| work_keys_str_mv | AT leitian correlationbetweengalectin3andadverseoutcomesinmyocardialinfarctionpatientsametaanalysis AT kanchen correlationbetweengalectin3andadverseoutcomesinmyocardialinfarctionpatientsametaanalysis AT zhihuahan correlationbetweengalectin3andadverseoutcomesinmyocardialinfarctionpatientsametaanalysis |